Skip to main content

Heron Therapeutics Value Stock - Dividend - Research Selection

Heron therapeutics

ISIN: US4277461020 , WKN: A1XB6K

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Heron Therapeutics, Inc., a biotechnology company, engages in developing medicines to address unmet medical needs. The company\'s product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, a neurokinin-1 receptor antagonist aprepitant for the prevention of CINV; and HTX-011, which is in Phase III clinical development for the prevention of post-operative pain. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Largest borrow rate increases among liquid names

2023-09-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

11 Best Long-Term Penny Stocks to Buy Now

2023-08-24
In this article, we will take a look at the 11 best long-term penny stocks to buy now. To see more such companies, go directly to 5 Best Long-Term Penny Stocks to Buy Now. The Federal Reserve’s historic battle against inflation that started in 2022 has highlighted the importance of an already-known fact: if you […]

Fly Intel: After-Hours Movers

2023-08-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Heron Therapeutics files to sell 21.9M shares of common stock for holders

2023-08-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

10 Health Care Stocks With Whale Alerts In Today's Session

2023-08-17
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Heron Therapeutics (HRTX) Reports Q2 Earnings: What Key Metrics Have to Say

2023-08-15
Although the revenue and EPS for Heron Therapeutics (HRTX) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call Transcript

2023-08-15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q2 2023 Earnings Call Transcript August 14, 2023 Heron Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.35 EPS, expectations were $0.23. Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Heron Therapeutics Second Quarter 2023 Earnings Conference Call. As a reminder, this conference […]

Q2 2023 Heron Therapeutics Inc Earnings Call

2023-08-15
Q2 2023 Heron Therapeutics Inc Earnings Call

Needham Reiterates Heron Therapeutics (HRTX) Buy Recommendation

2023-08-15

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

2023-08-15
Key Insights Institutions' substantial holdings in Heron Therapeutics implies that they have significant influence over...